Jordyn Sava is an editor for Targeted Oncology.
An analysis with longer follow-up of the ZUMA-3 study showed patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with brexu-cel had a median overall survival of 26 months and a complete response plus CR with incomplete count recovery rate of 71%.
In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.
Treatment with an anti-VEGF tyrosine kinase inhibitor appears safe for patients with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
In an interview with Targeted Oncology, John Strickler, MD, discussed the background and goals of the DeFianCe study in the colorectal cancer space.
Moving on to the dose-expansion study of a phase 1b/2a trial of fostroxacitabine bralpamide plus lenvatinib in hepatocellular carcinoma, investigators will assess the recommended phase 2 dose of 30 mg.
The secondary analysis of the phase 3 CONDOR study showed that given prior positron emission tomography, piflufolastat F 18 demonstrated changes in intended management, reinforcing the agent's clinical utility.
Based on findings from the phase 2b GT-201 and phase 3 ROMAN trials, the FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.
The combination of telisotuzumab vedotin and erlotinib did not lead to any unexpected safety signals and showed encouraging antitumor activity in patients with EGFR-mutated, c-Met protein expressing non–small cell lung cancer.
The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
The phase 1 dose-escalation portion of a phase 1/2 trial evaluating BT8009 in patients with urothelial cancer led to promising overall response and clinical benefit rates, including 1 complete response at the 5 mg/m2 dose.
The phase 1/2 BRUIN study of pirtobrutinib led to promising early efficacy in patients with B-cell malignancies who were heavily pretreated with richter transformation.
Data comparing 4 donor types showed matched sibling donors to be preferred in patients with myelofibrosis, according to a presentation given at the 2023 Transplantation and Cellular Therapy Meeting.
A new arm of the I-SPY 2 Endocrine Optimization Platform will investigate lasofoxifene in patients with clinically high-risk ER-positive/HER2-negative breast cancer who are molecularly low-risk.
The independent Data Monitoring Committee recommends the phase 3 study evaluating treatment with uproleselan in patients with relapsed/refractory acute myeloid leukemia to continue to the original planned final overall survival events trigger.
A phase 3 trial of bortezomib, dexamethasone, rituximab, and cyclophosphamide shortened the median time to first response and increased the number of patients with Waldenström's macroglobulinemia.
The upcoming THIO-102 trial will evaluate the safety and efficacy of THIO administered in sequence with pembrolizumab or atezolizumab across multiple tumor types.
Nivolumab plus cabozantinib led to superior overall survival, progression-free survival, overall response, duration of response, and complete response rates vs sunitinib in patients with advanced renal cell carcinoma.
Treatment with futibatinib is now available for patients with previously treated, unresectable, locally advanced or metastatic intrahepatic FGFR2-muatant cholangiocarcinoma.
In the biomarker analysis of the phase 3 NeoALTTO study, a small reduction in antimüllerian hormone levels were seen during 2 weeks of anti-HER2 treatment alone followed by a significant decline in most patients with HER2-positive breast cancer after combining with weekly paclitaxel.
Despite achieving the co-primary end points, the phase 3 PRESERVE trial of trilaciclib in patients with metastatic colorectal cancer will be terminated.
Neeta Somaiah, MD, discusses her presentation given at the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium.
The partial clinical hold was put on the phase 1/2 VELA study after visual adverse events were observed in some patients with solid tumors after treatment with BLU-222.
In an interview with Targeted Oncology, Zev A. Wainberg, MD, discussed the rationale behind NAPOLI 3 and how findings from the study will influence the metastatic pancreatic ductal adenocarcinoma space moving forward.
In phase 1 of the KOMET-001 trial, ziftomenib showed a 30% complete response rate in patients with NPM1-mutant acute myeloid leukemia treated at a dose of 600 mg. This is now the recommended phase 2 dose for the phase 2 portion of the study.
CINtec PLUS Cytology is the only dual-stain triage test to be offered by BioReference Health LLC for patients with a high-risk human papillomavirus result.
In an interview with Targeted Oncology, Tara Seery, MD, discussed the rationale and findings from cohort 3 of the QUILT 88 study in metastatic pancreatic cancer.
Updated findings from a phase 2 study have further confirmed the benefit of olutasidenib when used as a treatment option for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia.
Based on findings from the ROSALIA study, the FDA has accepted for review a proposed denosumab biosimilar for patients with osteoporosis and treatment-related bone loss in patients with cancer.
In a study examining racial disparities, differences in curative intent, endocrine and/or chemotherapy, frequency and types of treatment-related adverse events, and more were seen in Non-Hispanic Black women vs Non-Hispanic White women with breast cancer.
Wellmarker Bio’s novel therapeutic antibody WM-A1-3389 will be tested with Merck’s pembrolizumab in a phase 1b study of patients with non–small cell lung cancer.